PARP Inhibitor PJ34 Suppresses Osteogenic Differentiation in Mouse Mesenchymal Stem Cells by Modulating BMP-2 Signaling Pathway by Kishi Yuta et al.
Int. J. Mol. Sci. 2015, 16, 24820-24838; doi:10.3390/ijms161024820 
 





PARP Inhibitor PJ34 Suppresses Osteogenic Differentiation  
in Mouse Mesenchymal Stem Cells by Modulating BMP-2 
Signaling Pathway 
Yuta Kishi 1, Hisako Fujihara 1,2,*, Koji Kawaguchi 1, Hiroyuki Yamada 1, Ryoko Nakayama 3, 
Nanami Yamamoto 1, Yuko Fujihara 4, Yoshiki Hamada 1, Kazuhito Satomura 5 and  
Mitsuko Masutani 6,7 
1 Department of Oral and Maxillofacial Surgery, School of Dental Medicine,  
Tsurumi University 2-1-3 Tsurumi, Tsurumi-ku, Yokohama, Kanagawa 230-8501, Japan;  
E-Mails: kishi-y@tsurumi-u.ac.jp (Y.K.); kawaguchi-k@tsurumi-u.ac.jp (K.K.);  
yamada-hi@tsurumi-u.ac.jp (H.Y.); yamamoto-nanami@tsurumi-u.ac.jp (N.Y.);  
hamada-y@tsurumi-u.ac.jp (Y.H.) 
2 Department of Oral Hygiene, Tsurumi Junior College 2-1-3 Tsurumi, Tsurumi-ku, Yokohama, 
Kanagawa 230-8501, Japan 
3 Department of Pathology, School of Dental Medicine, Tsurumi University 2-1-3 Tsurumi,  
Tsurumi-ku, Yokohama, Kanagawa 230-8501, Japan; E-Mail: nakayama-r@tsurumi-u.ac.jp 
4 Department of Oral and Maxillofacial Surgery, Dentistry and Orthodontics,  
The University of Tokyo Hospital 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan;  
E-Mail: fujiharay-ora@h.u-tokyo.ac.jp 
5 Department of Oral Medicine and Stomatology, School of Dental Medicine,  
Tsurumi University 2-1-3 Tsurumi, Tsurumi-ku, Yokohama, Kanagawa 230-8501, Japan;  
E-Mail: satomura-k@tsurumi-u.ac.jp 
6 Department of Frontier Life Science, Graduate School of Biochemical Science,  
Nagasaki University 1-7-1 Sakamoto, Nagasaki 852-8588, Japan;  
E-Mail: mmasutan@nagasaki-u.ac.jp 
7 Division of Chemotherapy and Clinical Cancer Research,  
National Cancer Center Research Institute 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan;  
E-Mail: mmasutan@ncc.go.jp 
* Author to whom correspondence should be addressed; E-Mail: fujihara-h@tsurumi-u.ac.jp;  
Tel.: +81-45-580-8330; Fax: +81-45-581-1391. 
Academic Editor: Charles J. Malemud 
  
OPEN ACCESS
Int. J. Mol. Sci. 2015, 16 24821 
 
 
Received: 17 July 2015 / Accepted: 12 October 2015 / Published: 19 October 2015 
 
Abstract: Poly(ADP-ribosyl)ation is known to be involved in a variety of cellular  
processes, such as DNA repair, cell death, telomere regulation, genomic stability and cell 
differentiation by poly(ADP-ribose) polymerase (PARP). While PARP inhibitors are 
presently under clinical investigation for cancer therapy, little is known about their side 
effects. However, PARP involvement in mesenchymal stem cell (MSC) differentiation 
potentiates MSC-related side effects arising from PARP inhibition. In this study, effects of 
PARP inhibitors on MSCs were examined. MSCs demonstrated suppressed osteogenic 
differentiation after 1 µM PJ34 treatment without cytotoxicity, while differentiation of 
MSCs into chondrocytes or adipocytes was unaffected. PJ34 suppressed mRNA induction 
of osteogenic markers, such as Runx2, Osterix, Bone Morphogenetic Protein-2, Osteocalcin, 
bone sialoprotein, and Osteopontin, and protein levels of Bone Morphogenetic Protein-2, 
Osterix and Osteocalcin. PJ34 treatment also inhibited transcription factor regulators such 
as Smad1, Smad4, Smad5 and Smad8. Extracellular mineralized matrix formation was also 
diminished. These results strongly suggest that PARP inhibitors are capable of suppressing 
osteogenic differentiation and poly(ADP-ribosyl)ation may play a physiological role in this 
process through regulation of BMP-2 signaling. Therefore, PARP inhibition may potentially 
attenuate osteogenic metabolism, implicating cautious use of PARP inhibitors for cancer 
treatments and monitoring of patient bone metabolism levels. 
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1. Introduction 
Bone functions in a number of ways, including maintenance of organism structure, hematopoietic 
supply, mineral storage and so on. As the clinical importance of bone metabolism is high, protocols for 
osteogenic differentiation of mesenchymal stem cells (MSCs) are well established, with key markers for 
each differentiation step already identified [1–4]. During each step, required activation of specific 
transcription factors is controlled by factors such as bone morphogenetic protein (BMP), transforming 
growth factor-β (TGF-β), Wnt and hedgehog family proteins. 
Post-transcriptional and post-translational modifications play an essential role in cellular processes 
and biological functions. In these processes, poly(ADP-ribosyl)ation is known to be involved in many 
cellular processes, such as DNA repair [5,6], cell death [7], telomere regulation [8], chromatin function 
and genomic stability [9]. Poly(ADP-ribosyl)ation is catalyzed by the poly(ADP-ribose) polymerase 
family (PARPs) using nicotinamide adenine dinucleotide (NAD) as a substrate to target proteins that 
lead to biological activities. 
The most abundant PARP enzyme is PARP-1, whose deletion leads to increased sensitivity to anti-cancer 
drugs and ionizing radiation in mice [9,10]. PARP inhibitors also demonstrate sensitization to alkylating 
agents and ionizing radiation [11,12], and clinical trials for cancer therapy are now in progress [13]. 
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Moreover, it was shown that BRCA1/2-mutated breast cancer had high sensitivity to PARP inhibitors in 
clinical trials [14]. The mechanism of action of PARP inhibitors is competitive blocking of NAD+ from 
binding to PARP-1 to synthesize polymer of ADP-ribose [15]. However, little is known about the side 
effects of PARP inhibitors except associated nausea, fatigue, and anemia. [16]. In recent years, the 
involvement of PARP family members in MSC differentiation has also been reported [17–20], including 
involvement in chondrogenic differentiation with PARP cleavage and activation of caspase-3 [20],  
as well as negative effects of PARP-2 on adipogenic differentiation [17]. Indirect regulation of 
osteogenic differentiation by PARP-1 through control of Tumor Necrosis Factor expression has also 
been demonstrated [18,19]. However, to our best knowledge, the function of PARP in BMP-2 signaling 
during osteogenic differentiation has not been clarified. Thus, we speculated that PARP activity might 
possibly be involved in regulation of MSC differentiation, suggesting possible side effects of PARP 
inhibitors on MSCs during and after cancer therapy. 
In this study, we investigated the PARP inhibitors effects on proliferation and differentiation of two 
cell types. After determining PARP inhibitor concentrations demonstrating no cytotoxicity, the effects 
of PARP inhibitors on differentiation were analyzed. Our results would provide an understanding of 
biochemical osteogenic differentiation processes and theoretical basis for future clinical treatments using 
PARP inhibitors for cancer. 
2. Results 
2.1. Cytotoxicity Evaluation 
For the investigation of the cytotoxic effects of PARP inhibitors, PJ34 and AZD2281, on mouse  
bone marrow mesenchymal stem cells (BMMSCs) and mesenchymal progenitor cells (KUSA-A1 cells),  
two types of cytotoxic assays were performed. Inhibitors’ toxicity was concentration-dependent. In 
Microculture Tetrazolium Assay (MTT) assay, half maximal inhibitory concentration (IC50) for PJ34 on 
BMMSCs and KUSA-A1 cells after 24 h treatment was estimated at more than 10 µM. IC50 values for 
AZD2281 on BMMSCs and KUSA-A1 cells were both approximately 10 µM. However, cell viability 
was significantly reduced by PJ34 at 6 µM in BMMSCs and 4 µM in KUSA-A1. Viability was also 
significantly reduced by AZD2281 at 5 µM in BMMSCs and 3 µM in KUSA-A1 (Figure S1A,B). In 
survival assay, AZD2281 and a higher dose range of PJ34 were found to be cytotoxic for both cell types 
(Figure 1A,B). The cytotoxic effect of PJ34 was relatively mild and weaker than that of AZD2281, 
especially in KUSA-A1 cells. Concentrations of AZD2281 and PJ34 capable of suppressing cell survival 
by 50% were approximately 5.5 and 6.5 µM for BMMSCs, and 2 and 5 µM for KUSA-A1, respectively. 
From these results, 1–5 µM PJ34 was applied to assess PARP inhibitor effects with minimal cytotoxicity. 
2.2. Effects of PJ34 on Cell Proliferation 
Next, the effects of PJ34 on cell proliferation was analyzed. Dose-dependent suppressive effect of 
PJ34 on cell proliferation was exhibited (Figure 2A,B). Significant difference was not observed in the 
growth-rate of BMMSCs or KUSA-A1 cells cultured with 0 or 1 µM PJ34 during seven days, proving 
cells could maintain proliferation ability. However, cells cultured with 5 µM PJ34 showed significantly 
lower growth rates in both cell types. 




Figure 1. Cytotoxicity of PJ34 and AZD2281 on BMMSCs (A) and KUSA-A1 cells (B) 
were analyzed by survival assay. Cells were exposed to various concentrations of PARP 
inhibitors PJ34 and AZD2281 for 18 h, rinsed twice with PBS and allowed to grow for seven 
days. Values are expressed as mean ± SEM. * p < 0.05, ** p < 0.01, n.s. = no significance.  
 
Figure 2. Effects of PJ34 on cell proliferation of BMMSCs (A) and KUSA-A1 (B) by 
proliferation assay. Values are expressed as mean ± SEM. * p < 0.05, ** p < 0.01. 
2.3. Effects of PJ34 on Poly(ADP-ribosyl)ation 
To confirm that 1 and 5 µM PJ34 could effectively inhibit PARP activity, i.e., poly(ADP-ribosyl)ation, 
we analyzed poly(ADP-ribose) (PAR) levels after treatment with hydrogen peroxide to stimulate DNA 
damage. Immunocytochemical staining of anti-PAR antibody indicated that PJ34 treatment significantly 
reduced PAR synthesis in response to the treatment of hydrogen peroxide (Figure 3A,B). PAR level was 
reduced in cells treated with either 1 or 5 µM PJ34 proving that the utilized dose of PJ34 could inhibit 
PARP activity in both cell types. 





Figure 3. Inhibition of PARP activity in the presence of 1 and 5 µM PJ34 was confirmed  
by immunocytochemical analysis with anti-PAR antibody in BMMSCs (A) and KUSA-A1 
cells (B), respectively. Scale bars = 50 µm. 
2.4. Effects of PJ34 on Osteogenic, Adipogenic and Chondrogenic Differentiation of MSCs 
To investigate effects of the PARP inhibitor PJ34 on osteogenic differentiation of BMMSCs and 
KUSA-A1 cells, extracellular mineralized matrix formation was analyzed. Osteogenic differentiation 
status was determined by staining with Alizarin Red S for calcium deposition and von Kossa staining 
for deposition of calcium phosphate and calcium carbonate. The deposition level increased during 
osteogenic differentiation in time-dependent manner, however, these levels were significantly 
suppressed at each time point with 1 µM PJ34 treatment in BMMSCs (Figure 4A–C) and KUSA-A1 
cells (Figure 5A–C). 




Figure 4. Effects of PJ34 on osteogenic differentiation of BMMSCs were analyzed by 
visualizing calcium deposition with Alizarin Red S staining (A) and deposition of calcium 
phosphate and calcium carbonate with von Kossa staining (B); (C) Representative photos  
of Alizarin Red S staining and von Kossa staining of BMMSCs during osteogenic 
differentiation. Values are expressed as mean ± SEM. A.U. = Arbitrary Unit. * p < 0.05,  
** p < 0.01. 
 
Figure 5. Cont. 




Figure 5. Effects of PJ34 on osteogenic differentiation of KUSA-A1 cells were also 
analyzed by Alizarin Red S staining (A) and von Kossa staining (B); (C) Representative 
photos of Alizarin Red S staining and von Kossa staining of KUSA-A1 cells during 
osteogenic differentiation. Values are expressed as mean ± SEM. A.U. = Arbitrary Unit.  
* p < 0.05, ** p < 0.01. 
Chondrogenic and adipogenic differentiation of BMMSCs was analyzed using Alcian Blue staining 
and Oil Red O staining, respectively (Figure 6A–C). Only BMMSCs were analyzed since KUSA-A1 cells 
are mesenchymal progenitor cells, incapable of differentiating adipocyte or chondrocyte lineages [21]. 
During the examination period, almost the same level of staining was observed with or without 1 µM 
PJ34 in BMMSCs. Considering these differentiation patterns together, PJ34 appears to affect BMMSCs’ 
differentiation into osteoblasts, but not adipocytes or chondrocytes. 
 
Figure 6. (A) Effects of PJ34 on chondrogenic differentiation of BMMSCs were analyzed 
by Alcian Blue staining.; (B) Effects of PJ34 on adipogenic differentiation of BMMSCs were 
analyzed by Oil Red O staining; (C) Representative photos of Alcian Blue staining (Left) 
and Oil Red O staining (Right) of BMMSCs 21 days differentiation into chondrogenic and 
adipogenic, respectively. Values are expressed as mean ± SEM. A.U. = Arbitrary Unit.  
Scale bar = 500 µm. 
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2.5. Effects of PJ34 on the Osteogenic Differentiation Markers 
By quantitative real-time PCR, we examined the effects of PJ34 on the expression of mRNA for 
osteogenic differentiation markers, i.e., Runx2, Osterix (Osx), Bone Morphogenetic Protein-2 (BMP-2), 
Osteocalcin (OCN), bone sialoprotein (BSP), and Osteopontin (OPN), and regulators of transcription 
factors, such as Smad1, Smad4, Smad5 and Smad8. Additionally, alkaline phosphatase (ALP) and  
Parp-1 expression were also examined. Time-dependent increase of the mRNA expression levels of 
these factors was observed during osteogenic differentiation, which was significantly attenuated 
following PJ34 treatment at days 20 and 30 in both cell types (Figures 7 and 8). Parp-1 expression  
was also decreased with 1 µM in KUSA-A1 cells, during the differentiation process. As a result, it was 
proved that the expressions of mRNA for these osteogenic marker genes and transcription factors were 
suppressed by PJ34. 
2.6. Effects of PJ34 on Osteogenic Differentiation Marker Protein Levels 
To prove that BMP-2 expression could be regulated by PARP activity, protein levels of BMP-2 
signaling pathway elements were analyzed during osteogenic differentiation. Following exposure to  
1 µM PJ34 during 30 days of osteogenic differentiation, protein levels of BMP-2, Osterix and 
Osteocalcin were significantly attenuated (Figure 9). 
 
 
Figure 7. Cont. 




Figure 7. Effects of PJ34 on mRNA expression levels of osteogenic differentiation markers 
in BMMSCs and KUSA-A1 cells. Cells were treated with 0 and 1 µM PJ34 for 30 days, with 
medium changed every three days. The mRNA levels analyzed every 10 days were Runx2 
(A); Osterix (Osx) (B); Bone Morphogenetic Protein-2 (BMP-2) (C); Osteocalcin (OCN) (D); 
bone sialoprotein (BSP) (E); Osteopontin (OPN) (F); and alkaline phosphatase (ALP) (G). 
Values are expressed as mean ± SEM. * p < 0.05, ** p < 0.01. 
 
 
Figure 8. The effect of PJ34 on induction level of mRNA for transcription factors during 
osteogenic differentiation was also analyzed. Factors analyzed were Smad1 (A); Smad4 (B); 
Smad5 (C); and Smad 8 (D); Expression level of Parp-1 was also analyzed (E). Values are 
expressed as mean ± SEM. * p< 0.05, ** p < 0.01. 




Figure 9. (A) The effect of PJ34 on protein levels for BMP-2 signaling pathway elements 
of BMMSCs and KUSA-A1 cells during osteogenic differentiation. Relative band integrity 
was normalized by expression level of β-Actin. The proteins analyzed were BMP-2 (B) 
Osterix (C) and Osteocalcin (D). Values are expressed as mean ± SEM., ** p < 0.01. 
3. Discussion 
In this study, PARP inhibitor PJ34 delayed and suppressed osteogenic differentiation of BMMSCs 
and KUSA-A1 cells while chondrogenic and adipogenic differentiation were unaffected, suggesting that 
PARP activity could be involved in the osteogenic differentiation process especially after commitment 
into osteoblasts. MSCs have potential to be differentiated into several cell types, including osteoblasts, 
chondrocytes, adipocytes and so on [22–24]. However, regulation of the transcription factors during 
differentiation is not fully understood. We found that the mRNA expression levels (Figures 7 and 8) and 
protein expression levels (Figure 9) of the factors involved in BMP-2 signaling pathway in osteogenic 
differentiation were decreased following exposure to PJ34 suggesting that BMP-2 expression could be 
regulated by PARP activity (Figure 10). 




Figure 10. Schema of osteogenic differentiation through the BMP signaling pathway and 
possible regulation by PARP activity. (A) BMP-2 activates Smad1/5/8 (dark gray arrows) 
and upregulates Runx2 transcription to promote osteogenic differentiation. Runx2 induces 
expression of Osterix and accelerates transcription of Osteocalcin, Bone Sialoprotein, 
Osteonectin, and Osteopontin (brown thick arrows). PARP activity may also be involved in 
this pathway (black dotted arrows). Dotted lines are based on the results of this report;  
(B) PJ34 is suggested to suppress BMP-2 and Smad4 signaling (light gray arrows), leading 
to attenuation of mRNA levels for these factors (diagonal stripe arrows) and subsequent 
decrease in osteogenic differentiation. 
The role of poly(ADP-ribosyl)ation in the osteogenic differentiation process has not been fully 
elucidated and only two studies have reported involvement of PARP function in osteogenic 
differentiation. In the first, 3-Aminobenzamide (3-AB)—one of the first-generation PARP inhibitors that 
is not used for therapeutic purpose because of its low specificity [25]—was found to cause apoptotic cell 
death and osteogenic differentiation attenuation in SAOS-2 cells [26]. The second study reported that 
PAR signaling induced by hydrogen peroxide regulated cell death and osteogenic differentiation in 
SAOS-2 cells, a feature significantly enhanced by high doses of PJ34, PARP-1-silencing vector or 
PARG-silencing vector [27]. In general, PJ34 is applied at a dose of 10 µM (or 50 µM) for in vitro 
analysis of both cellular differentiation and cytotoxicity [28,29]. Different from the above studies, the 
dose of PJ34 used in this study was determined not to induce cytotoxicity based on the results of MTT 
assay and survival assay. 
To confirm inhibition of PARP activity after PJ34 treatment, PAR synthesis was analyzed after 
hydrogen peroxide stimulation (Figure 3), because we could not detect the synthesis of PAR without  
any stimulation. Theoretically, the mechanism of PJ34 is competitive blockade of NAD+ binding to  
PARP-1 (to synthesize PAR) [15] and PARP-1 mRNA levels are not considered to be affected. However, 
PARP-1 activity was reportedly reduced by 10 µM PJ34 in human colon and liver cancer cells [29]. 
Unexpectedly, we observed PARP-1 mRNA levels were significantly reduced by 1 µM PJ34 in  
KUSA-A1 cells but not in BMMSCs 20 and 30 days after PJ34 treatment (Figure 8E). Therefore, it is 
suggested that PJ34 could reduce PARP-1 mRNA expression levels in a dose- and time-dependent 
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manner in KUSA-A1 cells. The effect of PJ34 on PARP-1 has not been fully examined yet during this 
long duration, however, it is at least indicated that even 1 µM PJ34 could reduce synthesis of PAR and 
suppress osteogenic differentiation without showing particular cytotoxicity. 
Previous reports of PARP family member involvement in MSC differentiation [17–20], and our 
current study, suggest that the activity of specific PARP family member(s) promotes osteogenic 
differentiation via BMP-2 signaling. To further understand how PARP activity is involved in regulation 
of BMP-2 signaling during osteogenic differentiation, various interacting factors must be investigated—Wnt, 
hedgehog, Notch and TGF-β signaling—as relationships to poly(ADP-ribosyl)ation or cleavage of 
PARP have previously been reported in other cell lines [30–33]. 
PARP inhibition is currently considered as a novel molecular target drug for cancer therapy [11,14]; 
however, side effects of available PARP inhibitors have not been fully examined in clinical trials, in vivo 
or in vitro studies [16]. The delay and suppression of MSC osteogenic differentiation induced by PJ34 
treatment in this study indicate that PARP inhibitors have the potential to impede bone metabolism. 
Therefore, we suggest that clinical use of PARP inhibitors should be carefully considered, especially for 
cancer patients with bone metastasis, elderly patients with a high risk of fractures, and pediatric patients 
whose level of bone metabolism is being monitored. For future understanding for clinical application,  
it will therefore be necessary to investigate the effects of PARP inhibitor on differentiation and 
maturation of both osteoblast and osteoclast using in vivo models. 
4. Experimental Section 
All animal experimental procedures were approved by the Ethical Committee for Guidelines on 
Animal Experiments of Tsurumi University School of Dental Medicine on 3 July 2012 (No. 12040). 
4.1. Culture of Mouse Bone Marrow-Derived Mesenchymal Stem Cells 
Two types of cells, mouse bone marrow mesenchymal stem cells (BMMSCs) and mesenchymal 
progenitor cells (KUSA-A1 cells, RIKEN, Tsukuba, Japan, obtained 30 January 2013), were used in this 
study. BMMSCs were obtained from 6-week-old male C57BL/6 mice (CLEA, Tokyo, Japan) as 
previously described [34]. Briefly, BMMSCs were isolated from femurs of 6-week-old male C57BL/6 
mice and seeded into culture dishes. After being incubated for 4 h at 37 °C in 5% CO2, cells were washed 
twice with α-Minimum Essential Medium (α-MEM, Wako-Junyaku, Osaka, Japan). Growth medium 
consisted of α-MEM with 2 mM L-glutamax (Thermo Fisher, Waltham, MA, USA), 20% fetal bovine 
serum (FBS; Biowest, Nuaillé, France), 100 U/mL penicillin, 100 µg/mL streptomycin and 55 µM  
2-mercaptoethanol (Sigma-Aldrich, St. Louis, MO, USA). Primary cultures (passage 0 (P0)) were 
passaged to disperse colony-forming cells before seeding onto fresh culture dishes (P1). Growth medium 
was changed every three days and BMMSCs were passed 1:5 upon reaching confluence. 
4.2. MTT (Microculture Tetrazolium) Assay 
BMMSCs and KUSA-A1 cells were plated into 24-well plates at a density of 2.0 × 104 cells/well. 
After overnight incubation, culture medium was replaced with fresh medium containing various 
concentrations of either PARP inhibitor PJ34 (Sigma-Aldrich) or AZD2281 (ChemScene, Monmouth 
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Junction, NJ, USA). After being treated for 24 h, the number of viable cells was assessed using a  
3-(4-,5-dimethylthiazol-2-yl)-2,5-dyphenyl tetrazolium bromide (MTT; Sigma-Aldrich) assay as 
previously reported [35]. Briefly, 500 µg of MTT in 100 µL RPMI-1640 Medium (Sigma-Aldrich) was 
added to each well and incubated for 4 h at 37 °C. After incubation, medium was carefully removed and 
200 µL of 0.1 N HCl in isopropanol was added to each well to dissolve resultant formazan crystals. 
Absorbance was recorded at 570 nm using Microplate Reader Model 680 (Bio-Rad, Hercules, CA, USA) 
with a 96-well assay plate (Sumilon, Sumitomo Bakelite, Tokyo, Japan). All experiments were 
performed in triplicate. 
IC50 was calculated by Excel software (Microsoft, Redmond, Wachington, DC, USA), using the 
logarithm function. First, the concentration was plotted on the x-axis, and cell viability was plotted on 
the y-axis. Then, using the value of higher and lower sides of 50% of concentration and cell viability,  
a linear equation was created as follows: 
IC50 = 10^(log(A/B) × (50 − C)/(D − C) + log(B)) (1)
A: the concentration of higher side of 50% of cell viability, B: the concentration of lower side of 50% 
of cell viability, C: cell viability at the concentration of B, D: cell viability at the concentration of A, ^: 
symbol of power in Excel software. 
4.3. Survival Assay 
BMMSCs and KUSA-A1 cells were seeded into 12-well plates at a density of 2.0 × 103 cells/well 
and cultured in growth medium with various concentrations of either PARP inhibitors PJ34 or AZD2281 
for 18 h, rinsed two times in phosphate buffered saline (PBS) and allowed to grow. Cells were  
analyzed when cells cultured without PARP inhibitors reached confluence. Cells were fixed with 4% 
paraformaldehyde (PFA, Wako-Junyaku), stained with 0.02% crystal violet (Sigma-Aldrich) and the 
absorbance level was determined at 570 nm with Microplate Reader Model 680. 
Suppression of cell survival by 50% was also calculated using the same formula described above. 
IC50 = 10^(log(A/B) × (50 − C)/(D − C) + log(B)) (2)
A: the concentration of higher side of 50% of absorbance, B: the concentration of lower side of 50% of 
absorbance, C: reduction rate of absorbance at the concentration of B, D: reduction rate of absorbance 
at the concentration of A, ^: symbol of power in Excel software. 
4.4. Proliferation Assay 
BMMSCs and KUSA-A1 cells were seeded in triplicate into 6-well plates at a density of 4 × 103 cells/well 
in triplicate with growth medium containing 0, 1 or 5 µM PJ34. Culture medium was changed every  
3 days. Cell numbers were counted by hemocytometer. 
4.5. Immunocytochemical Detection of Poly(ADP-ribose) 
Poly(ADP-ribose) (PAR) synthesis was detected by immunocytochemical analysis as previously 
described [36] with a slight modification, as follows. BMMSCs and KUSA-A1 cells were seeded onto 
coverslips (Nunc, Rochester, NY, USA) and incubated with 0, 1 or 5 µM PJ34. Cells were treated with 
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500 µM hydrogen peroxide for 0, 10, 30 or 60 min, and fixed in ice-cold methanol for 10 min. After 
washing twice with PBS, cells were blocked in 0.1% bovine serum albumin (BSA; Sigma-Aldrich) 
diluted in PBS with 0.5% triton X-100 for 15 min. Subsequently, cells were incubated with anti-PAR 
antibody (1:200 dilution, Abcam, Cambridge, UK) at 4 °C overnight. After several PBS washes, 
coverslips were incubated with goat anti-chicken IgG (1:300 dilution, Vector Laboratories, Burlingame, 
CA, USA) at room temperature for 30 min. Bound antibody was visualized using an ABC Elite Detection 
Kit (Vector Laboratories) and 3,3’-diaminobenzidine substrate according to the manufacturer’s protocol. 
Coverslips were viewed with BX51 System Microscope (Olympus, Tokyo, Japan) and images were 
taken using a digital microscope camera (Olympus DP70). 
4.6. Osteogenic Cell Differentiation and Analysis 
Initially, BMMSCs and KUSA-A1 cells were seeded into 12-well plates at a density of 6 × 103 cells/well 
in growth medium and were cultured to confluence. Medium was then switched to osteogenic differentiation 
medium comprised of 5 µM ascorbic acid, 1 µM dexamethasone, 1 mM β-glycerophosphoric acid,  
100 U/mL penicillin, 100 µg/mL streptomycin, 55 µM 2-mercaptoethanol (all from Sigma-Aldrich) and 
2 mM L-glutamax (Thermo Fisher) in α-MEM [37] with or without PARP inhibitor PJ34 at 1 µM  
(day 0). Medium was freshly changed every 3 days. For analysis of osteogenic differentiation, von Kossa 
staining and Alizarin Red S staining were performed. Initially, culture medium was removed and cells 
were washed twice with PBS before fixation in 4% PFA for 25 min. After PFA was removed, cells were 
washed twice with distilled water and allowed to air dry. For detection of calcium, cells were stained 
with 1% Alizarin Red S (Sigma-Aldrich) adjusted to pH6.3 by ammonium hydroxide (Wako-Junyaku) 
for 15 min at 37 °C. Cells were washed twice with distilled water and incubated in 1 mL of 1% HCl in 
70% ethanol for 1 h at 4 °C, as previously reported [38]. Solutions (10 µL) were then applied to wells 
of a 96-well assay plate (Sumilon), and absorbance was determined at 450 nm by Microplate Reader 
Model 680 (Bio-Rad). For calcium phosphate and calcium carbonate detection, fixed cells were stained 
with 5% silver nitrate solution (Sigma-Aldrich) dissolved in distilled water for 1 h under UV light, before 
washing twice with distilled water. To analyze von Kossa staining in a time-course, photos were taken 
at each time point and digital images were analyzed by ImageJ software (NCI, Bethesda, MD, USA). 
All images were converted from color to gray scale in order to measure relative density and brightness. 
Density of crystal violet staining was also measured to confirm assessment of equal cellular densities 
between samples with or without PJ34 treatment. 
4.7. Chondrogenic Cell Differentiation and Analysis 
In this examination, BMMSCs were solely used because KUSA-A1 cells are mesenchymal progenitor 
cells, which are unable to differentiate into adipocytes or chondrocytes [21]. BMMSCs were seeded into 
12-well plates at a density of 6 × 103 cells/well in growth medium. After cell cultures reached confluence, 
growth medium was switched to chondrogenic differentiation medium containing 1 µM dexamethasone, 
0.17 mM ascorbic acid, 1 ng/mL transforming growth factor-β3 (TGF-β3), 1% insulin-transferrin-selenic 
acid (ITS) supplement, 100 U/mL penicillin and 100 µg/mL streptomycin in Dulbecco’s modified 
Eagle’s medium (DMEM; all from Sigma-Aldrich) [39], with or without 1 µM PJ34. For chondrogenic 
differentiation analysis, cultured cells were fixed and stained with 0.05% Alcian Blue solution (pH 2.5, 
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Wako-Junyaku) to detect glycosaminoglycans. To analyze chondrogenic differentiation levels in a  
time-course, photos of Alcian Blue staining were taken at each time point and digital images were 
analyzed by ImageJ software, as previously described. 
4.8. Adipogenic Cell Differentiation and Analysis 
Upon reaching confluence, growth medium was switched to adipogenic differentiation  
medium comprised of 1 µM dexamethasone, 1 µM insulin, 200 µM indomethacin, 0.5 µM  
3-isobutyl-1-methylxanthine, 100 U/mL penicillin, 100 µg/mL streptomycin (all from Sigma-Aldrich) 
and 10% FBS (Biowest) in DMEM, with or without 1 µM PJ34. After cell fixation in 4% PFA for  
25 min, cells were washed twice with 60% isopropanol. For lipid detection, cells were stained with Oil 
Red O solution (Wako-Junyaku) dissolved in 60% isopropanol for 20 min [40]. To analyze adipogenic 
differentiation levels over a time-course, photos of Oil Red O staining were taken at each time point and 
digital images were analyzed by ImageJ software, as previously described. 
4.9. Total RNA Extraction and Real-Time PCR 
Total RNA was isolated from cells by using TRIzol reagent (Invitrogen, Waltham, MA, USA) 
according to the manufacturer’s protocols. Isolated RNA (5 µg) was reverse transcribed to cDNA by 
using PrimeScript 1st Strand cDNA Synthesis Kit (Takara, Ohtsu, Shiga, Japan) according to the 
manufacturer’s protocols. Real-time PCR analyses were performed by using SYBR Premix Ex Taq II 
(Takara) and the StepOnePlus Real-Time PCR System (Applied Biosystems, Waltham, MA, USA)  
at recommended thermal cycling settings: one initial cycle at 95 °C for 30 s, followed by 40 cycles at  
95 °C for 3 s and 60 °C for 30 s. Primer details are summarized in Table 1. GAPDH was used as an 
internal control and quantitative gene expression was normalized to GAPDH expression level. 
Table 1. Sequence of primers used in real-time RT-PCR. 
Gene Length Forward Sequence (5′>3′) Reverse Sequence (5′>3′) 
Runx2 250 bp CCACCACTCACTACCACACG TCAGCGTCAACACCATCATT 
Osterix 373 bp ACCAGGTCCAGGCAACACACCTAC GCAGTCGCAGGTAGAACGCCCTGC 
BMP2 154 bp GGGACCCGCTGTCTTCTAGT TCAACTCAAATTCGCTGAGGAC 
Osteocalcin 302 bp AGACAAGTCCCACACAGCAG GGCGGTCTTCAAGCCATACT 
Bone sialoproiten 312 bp CTGAAGCAGGTGCAGAAGGA TCTGACCCTCGTAGCCTTCA 
Osteopontin 354 bp CTGGCAGCTCAGAGGAGAAG GGACATCGACTGTAGGGACG 
ALP 211 bp TAACACCAACGCTCAGGTCC GTGGTTCACCCGAGTGGTAG 
Smad1 97 bp ACCTGTGGCTTCCGTCTC ATCGTGGCTCCTTCGTC 
Smad4 145 bp CAGCACTACCACCTGGACTGGA CTGGAATGCAAGCTCATTGTGAA 
Smad5 197 bp AAGTAGATTCTGCCTGGGATT AGACGGTGGTGGGATGG 
Smad8 169 bp ATCCCTGGCAATCTGTA CCCTGGCTGTCCTGTAA 
PARP-1 72 bp GGAAAGGGATCTACTTTGCCG TCGGGTCTCCCTGAGATGTG 
GAPDH 240 bp TGATGACATCAAGAAGGTGGTGAAG TCCTTGGAGGCCATGTAGGCCAT 
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4.10. Western Blot Analysis 
BMMSCs and KUSA-A1 cells were lysed with RIPA buffer (10 mM Tris–HCl, 1% NP-40,  
0.1% SDS, 150 mM NaCl and 1 mM EDTA) containing protease inhibitor cocktail (Thermo Fisher), 
and each sample was centrifuged at 10,000× g, 4 °C for 20 min. NuPAGE LDS sample buffer 
(Invitrogen) was added to sample supernatant, subsequently samples were heated at 98 °C for 5 min. 
Samples (80 µg protein) were separated electrophoretically by the NuPAGE System with 12% Bis-Tris 
gel and electroblotted onto a polyvinylidene difluoride membrane by using an iBlot Dry Blotting System 
(all from Invitrogen). The membrane was blocked with 5% skim milk (Wako-Junyaku) at room 
temperature for 30 min, before primary antibody incubations were performed in 2.5% skim milk at 4 °C 
overnight. Antibodies used in this study were anti-BMP-2 (1:500 dilution, Bioss Antibodies, Woburn, 
MA, USA), anti-Osterix (1:1000 dilution, Bioss Antibodies), anti-Osteocalcin (1:500 dilution, Abcam) 
and anti-β-Actin (1:1000 dilution, Santa Cruz Biotechnology, Santa Cruz, CA, USA). Membranes were 
subsequently incubated with peroxidase-conjugated secondary antibody at room temperature for 30 min. 
Specific bands were detected with a chemiluminescence assay (Amersham ECL Prime Western Blotting 
Detection Reagent, GE Healthcare, Buckinghamshire, UK). Then, images were scanned by C-DiGit Scanner 
and analyzed using Image Studio Lite Software (both from Li-COR Biosciences, Lincoln, NE, USA). 
4.11. Statistical Analysis 
Group comparisons were undertaken using an independent t-test. All statistical analyses were 
performed using SPSS v.20.0 (IBM Corp., Armonk, NY, USA). 
5. Conclusions 
In this study, osteogenic differentiation of BMMSCs and KUSA-A1 cells was suppressed after 
treatment with 1 µM PARP inhibitor PJ34 without showing cytotoxic effects, and the mRNA and protein 
expression levels of the factors involved in BMP-2 signaling pathway were suppressed. On the contrary, 
chondrogenic and adipogenic differentiation of BMMSCs was not significantly affected. Therefore,  
the current in vitro study suggests that poly(ADP-ribosyl)ation could be involved in osteogenic 
differentiation through the BMP-2 signaling pathway. Moreover, our results also suggest that PJ34 
decreases bone metabolism, indicating a heightened need for careful indication of PARP inhibitors for 
cancer patients whose bone metabolism levels are being monitored. 
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